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Abstract
Background: Anti-cyclic citrullinated peptide (anti-CCP) antibodies are highly specific for RA, but are not
detectable in all RA patients. The aim of this study was to establish whether the clinical phenotypes of anti-CCP
positive and negative disease are distinct at the earliest clinically apparent phase of disease.
Methods: Patients were recruited from the Birmingham early inflammatory arthritis clinic. Participants were
included in the current study if they presented within 3 months of symptom onset and fulfilled 1987 ACR criteria
for RA at some point during an 18 month follow-up. Data were collected on demographic variables, joint
symptoms and tender (n = 68) and swollen (n = 66) joint counts. CRP, ESR, rheumatoid factor and anti-CCP2 status
were measured.
Results: 92 patients were included (48 anti-CCP positive). The anti-CCP positive and negative groups were
comparable in terms of demographic variables, inflammatory markers, joint counts and 1987 ACR classification
criteria, except that more anti-CCP positive patients were rheumatoid factor positive (83.3% vs. 11.4%, p < 0.01).
There was no significant difference in the pattern of joint involvement, except for an increased prevalence of knee
joint swelling in anti-CCP positive patients (42.9% vs. 22.2%, p = 0.03).
Conclusions: Patients with and without anti-CCP antibodies present in a similar way, even within three months of
clinically apparent disease that eventually develops into RA.
Background
Rheumatoid arthritis (RA) is a chronic, inflammatory
condition typically manifesting clinically as a symmetri-
cal polyarthritis. Rheumatoid synovitis is characterised
by complex leukocyte and cytokine networks. The per-
sistence of inflammation is mediated, in part, by the
stromal micro-environment, but the underlying causes
remain unclear [1,2]. Over the last decade there has
been particular interest in antibodies to citrullinated
peptides and proteins as important aetiological and pre-
dictive factors in early RA [3-5]. Citrullination of pro-
teins is a post-translational modification, which can
occur as a normal part of cell apoptosis [6]. However,
this process may induce antibody formation in suscepti-
ble individuals [7], which may predate clinical arthritis
by several years [8]. Subsequent environmental triggers
may enable anti-citrullinated protein/peptide antibodies
to enter joints and contribute to a chronic inflammatory
response [9].
Anti-cyclic citrullinated peptide (anti-CCP) antibodies
are highly specific for RA, but are not detectable in all
patients [10]. This raises the possibility that distinct
mechanisms exist for the pathogenesis of synovitis in
anti-CCP positive and negative patients. Indeed, anti-
CCP positive patients show both environmental and
genetic associations not present in anti-CCP negative
RA. For example, tobacco smoking is a well-recognised
risk factor for anti-CCP positive RA especially amongst
HLA-DRB1 individuals expressing the ‘shared epitope’
[11]. Furthermore anti-CCP positive patients have more
severe radiological destruction and poorer outcomes
[12], and synovial pathology appears to differ according
to anti-CCP status in the established phase of RA [13].
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2 years of symptom onset, suggested no clinical pheno-
typic differences according to anti-CCP status [12].
However, it is possible that as the disease evolves, all
RA patients, regardless of anti-CCP status, develop a
common pattern of joint involvement and that differ-
ences were not observed because the symptom duration
at inclusion was too heterogeneous. Moreover, there is
evidence that pathogenic mechanisms in the first few
months may differ from those in longer duration disease
and that this phase may be more responsive to therapy
[14,15]. Hence we aimed to establish whether the clini-
cal phenotypes of anti-CCP positive and negative disease
were distinct at the earliest clinically apparent phase of
RA, within 3 months of symptom onset.
Methods
Patients were recruited from the rapid access early
inflammatory arthritis clinic at Sandwell and West Bir-
mingham Hospitals NHS Trust. Patients referred to the
clinic by their General Practitioners were seen within
2 weeks. Participants were included in the current study
if they presented within 3 months of the onset of any
symptom attributed by the assessing Rheumatologist to
inflammatory joint disease (pain, stiffness, swelling), had
clinically apparent synovial swelling at baseline and ful-
filled 1987 American College of Rheumatology criteria
(ACR) for RA, either at baseline or during 18 months
follow-up [16].
Data were collected on patient demographic variables,
fulfillment of the ACR criteria, duration of symptoms
and whether the mode of onset was acute or insidious.
Tender (n = 68) and swollen (n = 66) joint counts were
performed. CRP, ESR, rheumatoid factor and anti-CCP2
status were measured at baseline. Radiographs were per-
formed of the hands and feet. Systematic clinical follow-
up was carried out at 1, 2, 3, 6, 12 and 18 months.
The anti-CCP positive and negative groups were com-
pared, with differences in means assessed using a two-
tailed unpaired student t-test. Proportions were
compared using a chi-squared test. Data analysis was
performed using the Statistical Package for Social
Sciences, version 17.0 (SPSS Institute, Chicago, IL,
USA). P values < 0.05 were considered significant.
Patients gave their informed consent prior to inclusion
into the programme. The study received ethical approval
from the local research ethics committee.
Results
At the time of this analysis 265 patients with an initial
symptom duration of less than 3 months and with com-
pleted follow-up had been recruited to the early synovi-
tis cohort; of these, 92 patients (34.7%) fulfilled 1987
ACR criteria for RA at some point during follow-up and
were included in the present study. Of these 92 patients,
48 patients had anti-CCP antibodies and 44 patients had
no anti-CCP antibodies at inclusion. There were an
additional 35 patients (13.2%) with persistent unclassi-
fied arthritis at the end of 18 month follow-up, all of
whom were anti-CCP negative. 21 of these patients were
treated with disease modifying anti-rheumatic drugs
(DMARDs); if such agents had not been used, it is pos-
sible that they may have eventually reached a diagnosis
of RA.
The patient groups were comparable in terms of gen-
der, age, ethnicity and smoking status (Table 1). In addi-
tion, patients had similar durations of symptoms and
modes of onset. There were no significant differences in
the presence or duration of morning stiffness. Moreover,
the other 1987 ACR criteria for RA were equally likely
to be present in the anti-CCP positive and negative
groups. This includes the presence of nodules and radi-
ological evidence of erosions, both of which were very
rare at presentation. The exception, however, was that
anti-CCP positive patients were significantly more likely
to be seropositive for rheumatoid factor (83.3% vs.
11.4%, p < 0.001). The mean number of ACR criteria
present at baseline was greater for anti-CCP positive
(3.73) than for anti-CCP negative patients (3.23) (p =
0.03). However, this was not significant after repeating
the analysis with rheumatoid factor status excluded.
There was also a significant difference in the proportion
of patients meeting at least 4 criteria needed for a diag-
nosis of RA at baseline (anti-CCP positive, 58.3%; anti-
C C Pn e g a t i v e ,3 6 . 4 % ;p=0 . 0 4 ) .H o w e v e r ,t h e r ew a sn o
difference in the mean time from symptom onset to the
fulfillment of classification criteria for RA (anti-CCP
positive, 158 days; anti-CCP negative, 131 days) in those
who did not fulfill classification criteria at baseline (Fig-
ure 1). It should be noted that the 1987 ACR criteria
stipulate that articular symptoms and signs should have
been present for at least 6 weeks; this criterion was
included in the present analysis. 28 patients who even-
tually fulfilled 1987 ACR criteria for RA (15 anti-CCP
positive, 13 anti-CCP negat i v e )w e r es e e ni nc l i n i c
within 6 weeks of the onset of symptoms and hence, by
definition, were unable to fulfill 1987 ACR critera for
RA at baseline. Of these, 15 patients (8 anti-CCP posi-
tive, 7 anti-CCP negative) would have met sufficient cri-
teria needed for diagnosis at baseline, had the 6 week
criterion been disregarded.
There were no significant differences in the total ten-
der or swollen joint counts, number of affected joint
areas or 28-joint score (as used in the DAS28 scoring
for RA, data not shown). In addition, inflammatory mar-
kers were comparable in both groups. Amongst different
joint regions, a significantly different prevalence of swel-
ling was only seen in the knee joint, with a higher
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22.8%, p = 0.03) (Figure 2).
Discussion
This study shows that RA patients with and without
anti-CCP antibodies present similarly, even within three
months of symptom onset. This is perhaps surprising
given the emerging consensus that anti-CCP positive
and negative states represent distinct clinical entities.
There is mounting evidence suggesting not only sepa-
rate molecular mechanisms underlying these two patient
groups, but also different genetic and environmental
predispositions as well as a different clinical progression.
However, consistent with a previous study of patients
presenting within 2 years of onset, our data provide evi-
dence that, despite these pathological differences, there
is a shared clinical phenotype for RA presentation
regardless of anti-CCP status. Not only do patients with
anti-CCP positive and negative disease present with
similar distributions of joint disease, but they also have
comparable ages of onset and levels of inflammation.
However, anti-CCP positive patients do fulfill
Table 1 Characteristics of patients with and without anti-CCP antibodie
anti-CCP positive (n = 48) anti-CCP negative (n = 44) P value
Female (n (%)) 28 (58.3%) 22 (50.0%) 0.42*
Age at inclusion, years (mean ± standard deviation) 56.6 ± 15.0 61.5 ± 14.7 0.12**
Ethnicity - Caucasian (n (%)) 38 (79.2%) 39 (88.6%) 0.22*
Smoking status - Current/ever smoked (n (%)) 31 (64.6%) 28 (63.6%) 0.92*
Symptom duration, days (mean ± standard deviation) 49.3 ± 20.2 56.4 ± 22.3 0.12**
Mode of onset (n (%))
Acute 25 (52.1%) 25 (56.8%) 0.65*
Insidious 21 (43.8%) 18 (40.9%)
Unspecified 2 (4.16%) 1 (2.27%)
Morning Stiffness
Duration, mins (mean ± standard deviation) 93.3 ± 89.5 123.8 ± 92.8 0.11**
No. patients ≥60 mins (n (%)) 28 (58.3%) 32 (72.7%) 0.15*
Symmetry (n (%)) 35 (72.9%) 33 (75.0%) 0.82*
Hand joint involvement (n (%)) 43 (89.6%) 41 (93.2%) 0.54*
≥ 3 joint areas involved (n (%)) 31 (64.6%) 30 (68.2%) 0.63*
Nodules (n (%)) 2 (4.17%) 1 (2.27%) 0.61*
Erosions (n (%)) 1 (2.08%) 2 (4.54%) 0.51*
Rheumatoid factor positive (n (%)) 40 (83.3%) 5 (11.4%) < 0.001*
1987 ACR criteria for RA
Total No. (mean ± standard deviation) 3.73 ± 1.09 3.23 ± 1.14 0.03**
No. fulfilling ≥ 4 criteria (n (%)) 28 (58.3%) 16 (36.4%) 0.04*
Tender joint count (max 68) (mean ± standard deviation) 8.33 ± 7.80 9.66 ± 8.90 0.45**
Swollen joint count (max 66) (mean ± standard deviation) 5.79 ± 4.51 7.07 ± 5.83 0.25**
ESR mm/hr (mean ± standard deviation) 32.3 ± 20.1 38.7 ± 29.3 0.23**
CRP mg/L (mean ± standard deviation) 29.0 ± 27.0 31.4 ± 30.8 0.70**
Statistical test applied: *Chi-squared test, **Unpaired student t-test
Figure 1 Cumulative proportion of patients fulfilling 1987 ACR
classification criteria for RA over 18 month follow-up period.
Solid line = anti-CCP antibody positive patients. Dashed line = anti-
CCP antibody negative patients.
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negative patients. This is predominantly due to the fact
that anti-CCP positive patients more often express rheu-
matoid factor, a well described phenomenon [17]. Con-
sequently, anti-CCP positive patients were more likely
to have met at least 4 criteria, thereby fulfilling classifi-
cation criteria for RA at initial presentation. However
there were no significant differences in the proportions
of patients meeting each of the other six 1987 ACR cri-
teria when then anti-CCP positive and negative patients
were compared.
This study has a number of limitations. Firstly, data
are available to suggest that seropositivity for anti-CCP
and rheumatoid factor are associated with delayed pre-
s e n t a t i o ni np a t i e n t sw i t hR A [18,19]. These surprising
observations raise the possibility that a subpopulation of
seropositive individuals were not seen early enough for
inclusion in our patient cohort. This may have intro-
duced selection bias. Secondly, the study may have been
underpowered to detect more subtle clinical differences
between patient groups. A retrospective power analysis
was carried out for each of the variables tested. This
showed that the study had an 80% power to detect a dif-
ference in proportions between anti-CCP positive and
negative groups of between 0.27 and 0.30 (27 to 30%)
depending upon the particular joint area under
consideration.
Interestingly, this study showed an increased likeli-
hood of knee involvement at presentation in anti-CCP
positive patients. This finding is consistent with other
results of previous studies which have shown that anti-
CCP positivity is associated with increased progression
of radiological destruction and that initial knee involve-
ment is also a positive predictor of greater radiological
damage [20]. Our data suggest that the previously
reported adverse outcomes of patients presenting with
knee involvement may be due to the increased probabil-
ity of anti-CCP seropositivity in such patients.
Conclusions
In summary, anti-CCP positive and negative patients
have similar baseline clinical presentations. This does
not necessarily conflict with current opinion that antibo-
dies to citrullinated peptides play an essential role in the
pathogenesis of RA. The role of anti-CCP status in pre-
dicting progression of undifferentiated early arthritis
into RA is well established [21,22], as is the association
with increased bone destruction. It is possible that the
shared clinical phenotype reported here may conceal dif-
ferences that are occurring at a pathological level. This
highlights the need to further investigate histological
changes in early RA, which may demonstrate differences
in anti-CCP positive and negative patients and have
important therapeutic implications.
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